Vertaling van "Proprietary drug " (Engels → Nederlands) :

proprietary drug | proprietary medicinal product | proprietary medicine | proprietary pharmaceutical product | proprietary preparation

generic | generic drug | generic medicament | generic medicinal product | generic medicine | generic pharmaceutical | generic pharmaceutical product | non-proprietary medicinal product

drug addiction [ drug abuse | drug-taking | fight against drugs | drug addicts(UNBIS) ]

Definition: This block contains a wide variety of disorders that differ in severity and clinical form but that are all attributable to the use of one or more psychoactive substances, which may or may not have been medically prescribed. The third character of the code identifies the substance involved, and the fourth character specifies the clinical state. The codes should be used, as required, for each substance specified, but it should be noted that not all fourth character codes are applicable to all substances. Identification of the psychoactive substance should be based on as many sources of information as possible. These include self-report data, analysis of blood and other body fluids, characteristic physical and psychological symptom ...[+++]s, clinical signs and behaviour, and other evidence such as a drug being in the patient's possession or reports from informed third parties. Many drug users take more than one type of psychoactive substance. The main diagnosis should be classified, whenever possible, according to the substance or class of substances that has caused or contributed most to the presenting clinical syndrome. Other diagnoses should be coded when other psychoactive substances have been taken in intoxicating amounts (common fourth character .0) or to the extent of causing harm (common fourth character .1), dependence (common fourth character .2) or other disorders (common fourth character .3-.9). Only in cases in which patterns of psychoactive substance-taking are chaotic and indiscriminate, or in which the contributions of different psychoactive substances are inextricably mixed, should the diagnosis of disorders resulting from multiple drug use (F19.-) be used. | Modifiers The following fourth-character subdivisions are for use with categories F10-F19: Code Title .0 Acute intoxication A condition that follows the administration of a psychoactive substance resulting in disturbances in level of consciousness, cognition, perception, affect or behaviour, o ...

European Monitoring Centre for Drugs and Drug Addiction [ EMCDDA [acronym] European Monitoring Centre for Drugs ]

conducting of drug and alcohol abuse tests | drug abuse tests conduct | conduct drug abuse tests | conducting of drug abuse tests

drug traffic [ drug trafficking | narcotics traffic | Drugs economy(STW) ]

accidental overdose of drug, wrong drug given or taken in error, and drug taken inadvertently accidents in the use of drugs, medicaments and biological substances in medical and surgical procedures (self-inflicted) poisoning, when not specified whether accidental or with intent to harm. Follow legal rulings when available (see note at Y10-Y34).

Definition: This category should be used when two or more psychoactive substances are known to be involved, but it is impossible to assess which substance is contributing most to the disorders. It should also be used when the exact identity of some or even all the psychoactive substances being used is uncertain or unknown, since many multiple drug users themselves often do not know the details of what they are taking. | misuse of drugs NOS

9. Stresses that the transfer of clean-energy technology to developing countries is central to tackling climate change and meeting the Millennium Development Goals; notes that at the 2005 Gleneagles summit, G8 leaders recognised the need for greater international co-operation and coordination of research and development of energy technologies; notes further that, at the same time, the Heads of Government of Brazil, Mexico, South Africa, China and India issued a joint statement with a view to building a new paradigm for international cooperation in the future, including improved participation in RD, international funding for technology transfer, and a concerted effort to address issues relating to Intellectual Property Rights (IPR); calls ...[+++] on the Commission to address IPR-related barriers to the acquisition of existing proprietary clean-energy technology through dialogue on the basis of further work analysing how international funds and public-private initiatives have fostered technology transfer covered by IPRs in other fields; calls on the Commission to explore the potential for new kinds of global public-private-partnerships in technologies to tackle climate change, drawing experience from international agreements to support IPR access to anti-retroviral drugs for developing countries.

All Member States are increasingly making use of various cost-absorbing mechanisms such as patients’ own participation in hospital, medical or drug costs, special agreements on drugs (price maintenance, or the use of proprietary medicines) or contracts between the purchasers of health services and service providers (fixed annual budgets or diagnosis-related pricing groups for hospitals).

Whereas it is also advisable to make the packaging of certain proprietary medicinal products, particularly sought after by drug addicts, less distinctive by removing the obligation to place a special mark on the outer packaging and the container of proprietary medicinal products classified as narcotics;

10. Considers, without prejudice to the application of the procedure provided for in Article 189b, that the objective of the above Community action programme must be to contribute to the fight against drug dependence, in particular by fostering cooperation between Member States, by supporting their action and by promoting the coordination of their prevention policies and programmes, and must include action aimed in particular at: - improving awareness of the problem of drugs and drug dependence and their consequences and of the means and methods of preventing drug dependence and the associated risks, in particular by using the informatio ...[+++]n supplied by the EDMC and the possibilities offered by existing Community programmes and instruments; - contributing to the improvement of information, education and training with a view to the prevention of drug dependence and the associated risks, especially for young people and particularly vulnerable groups". BLOOD SAFETY AND SELF-SUFFICIENCY - COUNCIL RESOLUTION "THE COUNCIL OF THE EUROPEAN UNION, RECALLING the Commission communication of 25 May 1993 on blood self- sufficiency in the European Community and its conclusions of 13 December 1993 on that communication; NOTES with interest the Commission communication of 21 December 1994 on blood safety and self-sufficiency in the European Community; REAFFIRMS the need to achieve self-sufficiency in blood and its derivatives in the Member States and in the Community, in particular through cooperation between Member States, in accordance with the principle of voluntary, unpaid blood donations; EMPHASIZES that the efforts to promote the quality and safety of blood collection help to prevent AIDS and other communicable diseases; RECALLS that Directive 89/381/EEC [1] which extends the scope of Directives 65/65/EEC and 75/319/EEC on proprietary medicinal products by laying down special provisions regarding medicines derived from human blood or plasma applies only to these products; ...